康缘药业(600557.SH)公告称,公司近日收到国家药品监督管理局签发的1类化学新药KYS2301凝胶(三种规格)的《药物临床试验批准通知书》。KYS2301凝胶为全球首个针对CCR8靶点的多肽抑制剂,适应症定位于特应性皮炎。临床前研究显示,KYS2301对CCR8靶点具有高亲和力,局部皮肤涂抹KYS2301凝胶对治疗特应性皮炎具有良好的药效作用,毒理学和药代动力学研究证明KYS2301凝胶安全性高。截至目前,该新药公司累计研发投入约4493万元。
康缘药业(600557.SH)公告称,公司近日收到国家药品监督管理局签发的1类化学新药KYS2301凝胶(三种规格)的《药物临床试验批准通知书》。KYS2301凝胶为全球首个针对CCR8靶点的多肽抑制剂,适应症定位于特应性皮炎。临床前研究显示,KYS2301对CCR8靶点具有高亲和力,局部皮肤涂抹KYS2301凝胶对治疗特应性皮炎具有良好的药效作用,毒理学和药代动力学研究证明KYS2301凝胶安全性高。截至目前,该新药公司累计研发投入约4493万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.